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Under use of statins in the elderly: The need for better health
care services research
The past thirty years have witnessed remarkable advances inmost important is the development of the HMG Co-A reductase
inhibitors, or “statins”. These medications have demonstrated
significant and consistent reductions in morbidity and mortality for
all patients with atherosclerotic disease. They are associated with a
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need for revascularization, and in myocardial infarction and stroke
rates.
In the setting of all this good news, it is imperative that the
benefits of these treatments accrue to all patients. Numerous
studies have documented that we currently fall well short of
universal application. The current study by Hoeks et al demon-
strates a particular aspect of the problem. These authors found that
the use of statins was significantly lower among elderly patients,
compared to younger patients, with peripheral artery disease.
Interestingly, the same was not true for other medical therapies
such as aspirin or beta blockers. These data highlight a concerning
and recurring observation that elderly patients are less likely to
receive evidence-based therapy than younger patients suffering the
same medical illness.
There may be many reasons for under use of evidence-based
therapy. For the elderly in particular, one major concern is fear of
side effects. Most practitioners recognize that the elderly are more
susceptible to side effects and complications, and this understand-ably leads to a greater reticence to prescribe. What frequently goes
unrecognized, however, is that the elderly stand to benefit more
from evidence-based therapy. Their risk of MI or stroke is much
higher and therefore the potential benefit is as well, usually offset-
ting any increased risk of side effects. The few studies of statins in
elderly patients corroborate this.
It is interesting that only statins were subject to under use in
elderly patients. This suggests something peculiar to statins in the
elderly that leads to lower use. This may be due to a greater risk of
side effects, a greater concern for side effects, or both. As with any
good study, this one raises more questions than it answers. Obser-
vations such as these call for further study to identify the causes,
and improve performance.
Few opportunities in modern medicine are as great as the
better application of already proven therapies. Yet far fewer re-
sources are devoted to this, compared with those applied to drug
development and discovery. We must commit more resources to
this area. It is hard to imagine a more productive use for research
dollars.
